Role of Serotonin in Alzheimer's Disease

Geldenhuys, Werner I.; Van der Schyf, Cornelis I.
September 2011
CNS Drugs;2011, Vol. 25 Issue 9, p765
Academic Journal
Mounting evidence accumulated over the past few years indicates that the neurotransmitter serotonin plays a significant role in cognition. As a drug target, serotonin receptors have received notable attention due in particular to the role of several serotonin-receptor subclasses in cognition and memory. The intimate anatomical and neurochemical association of the serotonergic system with brain areas that regulate memory and learning has directed current drug discovery programmes to focus on this system as a major ther- apeutic drug target. Thus far, none of these programmes has yielded un- ambiguous data that suggest that any of the new drug entities possesses disease-modifying properties, and significantly more research in this promis- ing area of investigation is required. Compounds are currently being in- vestigated for activity against serotonin 5-HT1, 5-HT4 and 5-HT6 receptors. This review concludes that most work done in the development of selective serotonin receptor ligands is in the pre-clinical or early clinical phase. Also, while many of these compounds will likely find application as adjuvant therapy in the symptomatic treatment of Alzheimer's disease, there are currently only a few drug entities with activity against serotonin receptors that may offer the potential to alter the progression of the disease.


Related Articles

  • Kinetics of serotonin oxidation by heme-Aβ relevant to Alzheimer's disease. Mukherjee, Soumya; Seal, Manas; Dey, Somdatta // Journal of Biological Inorganic Chemistry;Dec2014, Vol. 19 Issue 8, p1355 

    Serotonin (5-HT) is an essential neurotransmitter for cognitive functions and formation of new memories. A deficit in 5-HT dependent neuronal activity is somewhat specific for Alzheimer's disease. Metal-mediated oxidative degradation of neurotransmitters by Aβ bound to metals has been...

  • The Potential Utility of 5-HT1A Receptor Antagonists in the Treatment of Cognitive Dysfunction Associated with Alzheimer's Disease. Schechter, L.E.; Dawson, L.A.; Harder, J.A. // Current Pharmaceutical Design;Jan2002, Vol. 8 Issue 2, p139 

    The 5-HT1A receptor has been extensively studied over the last two decades. There is a plethora of information describing its anatomical, physiological and biochemical roles in the brain. In addition, the development of selective pharmacological tools coupled with our understanding of...

  • New Insights into Serotonin 5-HT4 Receptors : A Novel Therapeutic Target for Alzheimer's Disease? Maillet, Marjorie; Robert, Sylvain J.; Lezoualc'h, Frank // Current Alzheimer Research;Apr2004, Vol. 1 Issue 2, p79 

    The serotonin 5-HT4 receptor mediates many physiological effects in the central nervous system. The recent molecular identification of 5-HT4 receptors and the development of selective 5-HT4 receptor ligands have led to many important new insights into the signalling pathways and the...

  • An Overview of the Current and Novel Drugs for Alzheimer's Disease with Particular Reference to Anti-Cholinesterase Compounds. Colombres, Marcela; Sagal, Juan Paulo; Inestrosa, Nibaldo C. // Current Pharmaceutical Design;Oct2004, Vol. 10 Issue 25, p3121 

    Several cellular processes could be targeted if the complex nature of Alzheimer' s disease (AD) was already understood. Most of AD treatments have been focused on the inhibition of acetylcholinesterase (AChE) in order to raise the levels of its substrate, i.e. the neurotransmitter acetylcholine...

  • RESEARCH DIGEST. Kaplan, Deborah // Patient Care for the Nurse Practitioner;May2006, Vol. 9 Issue 5, p9 

    The article reports on the results of several medical studies as of May 2006. Cholinesterase inhibitor donepezil improves cognition and preserves function in patients with severe Alzheimer's disease. Some patients with major depression who are unresponsive to the selective serotonin reuptake...

  • A BREAKTHROUGH IN TREATING DEMENTIA? Olszewska, Karolina // Warsaw Voice;Sep2015, Issue 9, p14 

    The article offers information on the project New non-amyloid treatment of cognitive disorders (NATCo) conducted by Polish researchers for developing drug for treatment of Alzheimer's disease. Topics discussed include serotonin receptors being target of the drug, use of drug in improvement of...

  • Memory affected by single gene.  // New Scientist;10/25/2003, Vol. 180 Issue 2418, p17 

    A single gene has a profound effect on short-term memory skills, making a significant difference to how many words people can remember from a list. The neurotransmitter serotonin is best known for its role in depression, but drugs that block a particular serotonin receptor in the brain also...

  • Cognitive Intervention in Alzheimer's Disease. Geiger, Brian F. // Journal of Rehabilitation;Jul-Sep88, Vol. 54 Issue 3 

    Focuses on the use of cognitive therapy for Alzheimer's disease in the United States. Clinical background of the illness; Identification of the disease; Implementation of the strategy known as expanded rehearsal technique in the rehabilitation of persons with Alzheimer's disease.

  • Donepezil improved the clinical state and quality of life in moderate-to-severe Alzheimer disease. Luckmann, Roger // ACP Journal Club;Mar/Apr2002, Vol. 136 Issue 2, p59 

    Focuses on a study which assessed the effectiveness of donepezil for the improvement of global function, cognition, and behavior in patients with moderate-to-severe Alzheimer disease. Methodology of the study; Results; Comments on the study.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics